Literature DB >> 11823762

Use of a spontaneous adverse drug events database for identification of unanticipated drug benefits.

Allen Brinker1, Julie Beitz.   

Abstract

We describe an examination of a spontaneous adverse events database in an effort to identify agents with possible hitherto unknown antiangiogenic properties. The surrogate end point was abnormal wound healing. This analysis represents use of this database for identification of a possibly useful in vivo side effect. Through thoughtful choice of end points, we believe spontaneous adverse events databases have the capacity for hypothesis generation in a search for unanticipated beneficial drug properties.

Mesh:

Substances:

Year:  2002        PMID: 11823762     DOI: 10.1067/mcp.2002.120677

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions.

Authors:  Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 2.  A Systematic Review and Meta-analysis of the Adverse Effects of Levonorgestrel Emergency Oral Contraceptive.

Authors:  Nattawut Leelakanok; Janthima Methaneethorn
Journal:  Clin Drug Investig       Date:  2020-05       Impact factor: 2.859

3.  Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.

Authors:  Allen D Brinker; Jenna Lyndly; Joseph Tonning; David Moeny; Jonathan G Levine; Mark I Avigan
Journal:  Drug Saf       Date:  2013-12       Impact factor: 5.606

Review 4.  Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors.

Authors:  Shewit Bezabeh; Ann Corken Mackey; Paul Kluetz; Dilara Jappar; Joyce Korvick
Journal:  Oncologist       Date:  2012-04-03

5.  Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin.

Authors:  Allen Brinker; Lawrence Goldkind; Renan Bonnel; Julie Beitz
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.

Authors:  Christopher Rowan; Allen D Brinker; Parivash Nourjah; Jennie Chang; Andrew Mosholder; Jeffrey S Barrett; Mark Avigan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-04       Impact factor: 2.890

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.